EUVIMEDEUVIMED entdecken
Crossref

Abstract FR604: The Roller-Coaster of Blood Pressure: Recurrent Post-Bortezomib Hypertensive Urgency and Antihypertensive Titration Challenges in a Haemodialysis Patient

Preeti Elizabeth Jossy, Srushti Shankar, Deep Phachu

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.fr604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Preeti Elizabeth Jossy und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Case Presentation: A 68 year old female with multiple myeloma and end stage renal disease (ESRD) on haemodialysis presented with recurrent episodes of severe hypertension temporally associated with chemotherapy. Her regimen included bortezomib, daratumumab, IVIG and corticosteroids. Across hospitalizations, she developed marked post infusion BP elevations up to 240/140 mmHg with associated headaches and chest pain followed by gradual normalization prior to the next treatment cycle. Differential Diagnosis: Differentials included chemotherapy induced hypertension, secondary hypertension, ESRD related volume overload, corticosteroid associated hypertension, acute coronary syndrome and aortic dissection. CT angiography excluded aortic dissection, while serial troponins, electrocardiography and echocardiogram were not suggestive of acute coronary syndrome. Although ESRD likely contributed to baseline hypertension, the patient's recurrent blood pressure spikes immediately following each bortezomib infusion, followed by gradual improvement over two weeks corresponding to her chemotherapy cycles. Treatment and Management: The patient demonstrated persistent, treatment refractory hypertension despite multiple antihypertensive agents, including valsartan, carvedilol, amlodipine, hydralazine, and doxazosin, with limited response even to intravenous therapy. Notably, blood pressure elevations followed a reproducible cyclical pattern, peaking shortly after bortezomib infusion and gradually returning toward baseline over 2 weeks before the next treatment cycle. Outcome and Follow-Up: This pattern contributed to recurrent difficult to control hypertension despite minimal long term antihypertensive escalation. The phenomenon highlights a significant clinical conundrum, particularly in ESRD patients with labile hemodynamic where balancing antihypertensives risks both refractory hypertension and interval hypotension. This issue is further amplified in patients on home peritoneal dialysis, where less frequent monitoring complicates safe medication adjustment. Key Takeaways: Bortezomib may be a cause of recurrent, severe, and temporally patterned hypertension. ESRD patients are particularly vulnerable due to baseline labile hemodynamics. Antihypertensive regimens may require dynamic, cycle based titration rather than static intensification. Failure to deescalate therapy between cycles may increase hypotension risk, especially in dialysis dependent patients.

Zitieren

APA

Jossy, P. E., Shankar, S., & Phachu, D. (2026). Abstract FR604: The Roller-Coaster of Blood Pressure: Recurrent Post-Bortezomib Hypertensive Urgency and Antihypertensive Titration Challenges in a Haemodialysis Patient. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr604

Vancouver

Jossy PE, Shankar S, Phachu D. Abstract FR604: The Roller-Coaster of Blood Pressure: Recurrent Post-Bortezomib Hypertensive Urgency and Antihypertensive Titration Challenges in a Haemodialysis Patient. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr604

BibTeX
@article{Jossy2026,
  author = {Jossy, Preeti Elizabeth and Shankar, Srushti and Phachu, Deep},
  title = {Abstract FR604: The Roller-Coaster of Blood Pressure: Recurrent Post-Bortezomib Hypertensive Urgency and Antihypertensive Titration Challenges in a Haemodialysis Patient},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.fr604}
}
Kostenlos starten →